Can biomarkers guide organ-sparing treatment for stomach and esophagus cancer?
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if using specific biomarkers (like HER2 and PD-L1) can help choose the best treatment to potentially avoid surgery. It aims to preserve the stomach or esophagus while effectively treating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach, esophagus, or gastroesophageal junction cancer that can be surgically removed and is stage II or higher.
- Your cancer cells must show a certain level of PD-L1 (a protein that can help cancer hide from the immune system).
- You are willing to have biopsies and blood samples taken to check for biomarkers.
- You have adequate organ function and are in generally good health (ECOG performance status 0 or 1).
- You have not had prior treatment with certain targeted therapies or checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can improve outcomes for patients with a certain type of stomach or esophageal cancer that can be surgically removed. It aims to see if this approach shrinks tumors and helps prevent recurrence.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.